Relay Therapeutics, Inc.

Relay Therapeutics, Inc. is a clinical-stage precision medicine company dedicated to transforming the drug discovery process. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company's core mission is to develop life-changing small molecule therapies for patients with cancer and genetic diseases. It achieves this by leveraging its proprietary Dynamo™ platform, which integrates advanced computational and experimental approaches to gain unparalleled insights into protein motion and function.

Relay Therapeutics is advancing a diverse pipeline of therapeutic candidates focused on precision oncology and genetic diseases. Key programs include Zovegalisib (RLY-2608), a pan-mutant and isoform-selective PI3Kα inhibitor currently in Phase 3 clinical trials for HR+/HER2- metastatic breast cancer and also under investigation for PI3Kα-driven vascular anomalies. The company's portfolio also features an investigational non-inhibitory chaperone for Fabry disease and programs targeting NRAS-driven solid tumors. Additionally, Lirafugratinib (RLY-4008), an oral, selective FGFR2 inhibitor, has been out-licensed to Elevar Therapeutics.

Under the leadership of President and CEO Sanjiv K. Patel, M.D., Relay Therapeutics continues to advance its pipeline. In April 2026, the company announced positive clinical data for its Zovegalisib plus Atirmociclib triplet combination, supporting its progression into Phase 3 development for frontline metastatic breast cancer. This strategic advancement, along with other pipeline developments, has led several analyst firms to recently increase their price targets for RLAY shares, reflecting a positive market positioning for the company.